Estrella Immunopharma, Inc. (ESLAW) income statement
ESLAWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLA
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.06+0.00 (0.00%)
Close on Nov 20, 2026Market cap $13.96MP/E –Yield –
Estrella Immunopharma, Inc. financial ratios
See a number that looks wrong?